DataString Consulting Company Logo
DataString Consulting Company Logo
Vutrisiran Market
Home»Recent Reports»Vutrisiran Market

Vutrisiran Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802062, Published - March 2025

Segmented in Therapeutic Application (ATTR Amyloidosis, Familial Amyloid Polyneuropathy, Wild Type ATTR cardiomyopathy, Others), Drug Mechanism (siRNA therapy, TTR gene silencing, RNA interference-based therapy), Distribution Channel, Producer Type, End User and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Vutrisiran Market Outlook

The market, for Vutrisiran was estimated at $832.8 million in 2024; and it is anticipated to increase to $2.3 billion by 2030 with projections indicating a growth to around $5.3 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 18.3% over the forecast period. In today's evolving healthcare environment Vutrisiran plays a crucial role that cannot be emphasized enough. The impressive growth path its currently following is mainly due to its impact in genetic biomedicine. Witnesses have observed a rising interest in it largely fueled by reasons. Notably its vital role in managing hereditary transthyretin mediated (hATTR) amyloidosis advancements in genetic medicine technology and the increase, in worldwide healthcare expenditures. The products ability to transform the field of amyloidosis treatment contributes to its continued importance, in the pharmaceutical and healthcare sectors.


Vutrisiran is a RNA interference (RNAi) based treatment known for its effectiveness in targeting and decreasing the levels of transthyretin (TTR) a protein linked to the advancement of hATTR amyloidosis disease progression worldwide. Its popularity continues to grow thanks to advancements, in genetic medicine and the rising cases of amyloidosis.


Market Size Forecast & Key Insights

2019
$832M2024
2029
$4.5B2034

Absolute Growth Opportunity = $3.6B

The Vutrisiran market is projected to grow from $832.8 million in 2024 to $4.47 billion in 2034. This represents a CAGR of 18.3%, reflecting rising demand across Hereditary Transthyretin-Mediated Amyloidosis (hATTR) and Polyneuropathy Management.

The Vutrisiran market is set to add $3.6 billion between 2024 and 2034, with manufacturer targeting Familial Amyloid Polyneuropathy & Wild Type ATTR cardiomyopathy Therapeutic Application projected to gain a larger market share.

With Emerging therapies in transthyretin-mediated amyloidosis , and Expanding rna interference technology, Vutrisiran market to expand 437% between 2024 and 2034.

Opportunities in the Vutrisiran Market

Strategic Collaborations for Global Expansion

Collaborating with pharmaceutical companies worldwide can help expand the reach and impact Vutrisiran has on a broader scale by forming strategic alliances, for product distribution and licensing agreements to enter new markets and enhance its presence globally.

Bridging the Gap in Therapeutic Areas and Technological Advancements in Drug Delivery

Vutrisirans role as an RNA interference based treatment shows potential in meeting the requirements for hereditary transthyretin mediated amyloidosis . Its distinct ability to silence genes offers hope, in addressing this yet severe disease that has been historically overlooked in terms of treatment options and could lead to substantial revenue generation and market expansion.

Recent progress in drug delivery using nanoparticles has created opportunities for RNA interference treatments such as Vutrisiran. By harnessing these methods Vutrisiran is able to achieve improved absorption and precise delivery to specific areas leading to enhanced effectiveness in medical settings and increased patient adherence. This could potentially boost the acceptance and usage rate for Vutrisiran, in the market.

Growth Opportunities in North America and Europe

Europe Outlook

Europe emerges as a player in the Vutrisiran market scenario due to the high prevalence of peripheral neuropathy in the region. The UK, Germany, and France stand out thanks to their healthcare systems and history embracing technology. Despite facing competition, from other RNA based treatments Vutrisiran stands out for its precise molecular targeting and less frequent dosages.

North America Outlook

Without a doubt and indisputably so—North America takes the lead in the Vutrisiran market with a focus on the United States as its primary player in this field. The remarkable growth observed in this region is primarily driven by the higher incidence rates seen in hereditary transthyretin mediated amyloidosis along with a healthcare sector that is progressively adopting cutting edge treatments like Vutrisiran. Essentially speaking and at its core essence—the innovative RNA interference technology utilized by Vutrisiran aligns with the healthcare trends prevalent in this region This alignment has led to an increased usage among patients grappling with hATTR thereby spurring its demand across the board. Nevertheless and yet,—the substantial presence and competition, from alternative therapies could potentially pose a significant hurdle challenge moving forward. North America is poised for growth with backing and a thriving investment environment that emphasizes genetic and rare disease treatments – factors that could fuel the success potential, for Vutrisiran.

North America Outlook

Without a doubt and indisputably so—North America takes the lead in the Vutrisiran market with a focus on the United States as its primary player in this field. The remarkable growth observed in this region is primarily driven by the higher incidence rates seen in hereditary transthyretin mediated amyloidosis along with a healthcare sector that is progressively adopting cutting edge treatments like Vutrisiran. Essentially speaking and at its core essence—the innovative RNA interference technology utilized by Vutrisiran aligns with the healthcare trends prevalent in this region This alignment has led to an increased usage among patients grappling with hATTR thereby spurring its demand across the board. Nevertheless and yet,—the substantial presence and competition, from alternative therapies could potentially pose a significant hurdle challenge moving forward. North America is poised for growth with backing and a thriving investment environment that emphasizes genetic and rare disease treatments – factors that could fuel the success potential, for Vutrisiran.

Europe Outlook

Europe emerges as a player in the Vutrisiran market scenario due to the high prevalence of peripheral neuropathy in the region. The UK, Germany, and France stand out thanks to their healthcare systems and history embracing technology. Despite facing competition, from other RNA based treatments Vutrisiran stands out for its precise molecular targeting and less frequent dosages.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, China, Japan, United Kingdom are expected to grow at 17.6% to 25.6% CAGR

2

Emerging Markets : Brazil, Indonesia, South Africa are expected to grow at 13.7% to 19.0% CAGR

Market Analysis Chart

Garnerin significant interest worldwide is Vutrisiran. A groundbreaking RNA interference . Its promising potential in combatting ATTR amyloidosis. An ailment. has been turning heads globally. The escalating cases o ATTR amyloidosis round the world paired with the scarceness o effective treatments have fueled the market growth, for Vutrisiran significantly. Moreover folks are drawn to Vutrisiran cause o its utilization o innovative RNA interference technology in its development.

Recent Developments and Technological Advancement

December 2024

MacroBiotech completed the third phase trials for Vutrisiran with outcomes, for individuals suffering from hereditary transthyretin mediated amyloidosis .

October 2024

Mediline Inc announced its intentions to increase the manufacturing output for Vutrisiran to meet the growing needs, in the sector focused on hATTR treatments.

August 2024

Vision Pharmaceuticals announced an increase in research and development funding for vutrisiran. They have commenced conducting a range of in depth studies to investigate its effectiveness, in addressing neurological conditions beyond its current use.

Vutrisiran, an innovative therapeutic solution, has been at the forefront of significant strides in the medical landscape recently. This injection-based treatment is under vigorous scrutiny by researchers aiming to expand its applicability and thereby broaden market reach; indeed, its efficacy in treating hereditary transthyretin-mediated amyloidosis has garnered critical acclaim and stimulated growth.

Impact of Industry Transitions on the Vutrisiran Market

As a core segment of the Pharmaceutical industry, the Vutrisiran market develops in line with broader industry shifts. Over recent years, transitions such as Emergence in Rare Disease Management and Influence in Genetic Therapy Research have redefined priorities across the Pharmaceutical sector, influencing how the Vutrisiran market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Emergence in Rare Disease Management:

Vutrisiran, a novel RNA interference therapeutic, has become a beacon of change in the healthcare arena, especially in tackling rare diseases. This transition has been significantly impactful, with Vutrisiran demonstrating a strong potential in treating Amyloidosis, a rare, hereditary condition. Its introduction has heralded an era where patients with rare diseases can hope for better health outcomes, improved quality of life, and longterm disease management. The capability of Vutrisiran to silence specific genes demonstrates a groundbreaking approach to drug development, setting a precedent for other pharmaceutical players.

2

Influence in Genetic Therapy Research:

The widespread use and positive outcomes seen with Vutrisiran have had an impact on the realm genetic therapy exploration This latest shift in the field highlights once more the value that RNA interference technologies bring into genetic medicines landscape. including Vutrisiran itself The triumphs seen with Vutrisiran have sparked greater financial support and enthusiasm for genetic therapy studies thereby leading to progress in developing new therapies, for different genetic conditions.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Vutrisiran market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Emerging Therapies in Transthyretin-Mediated Amyloidosis , and Aging Global Population and associated increase in Rare Diseases

Vutrisiran is also a RNA interference medication designed to combat the production of harmful proteins in patients with ATTR disease. The medical community increasingly acknowledges the pressing demand for therapies in this area. As Vutrisiran also advances it emerges as an option for treating ATTR providing a less frequent dosaging regimen and a hopeful substitute, to current therapies.
The longer people live worldwide leads to an occurrence of uncommon genetic conditions like ATTR disease on a larger scale as well This situation highlights the increasing need for treatments particularly in the area focusing on genetic disorders Therefore Vutrisiran which employs a precise technique, to silence genes is also expected to experience significant growth in its market value.
The placement Vutrisiran has also in the growing RNA interference technology sector is also significant strategically. This advanced field within biotechnology shows promise and is also projected to experience rapid growth in the future. It offers a foundation, for Vutrisiran and boosts its market prospects.

Restraint: Regulatory Challenges

The healthcare field is recognized for its regulations and Vutrisiran faces similar scrutiny as partakings in this tightly regulated domain are subject to oversight measures as well. Securing the approval from entities like the Food and Drug Administration and the European Medicines Agency is vital for a successful market entry. Nevertheless the extended evaluation processes complicated by alterations, in regulatory protocols can pose a substantial obstacle to market expansion. Delays, in getting approvals might slow down the process for Vutrisiran to reach the sector and could affect market demand and dynamics significantly.

Challenge: Competition from Similar Therapies

The pharmaceutical sector is expanding rapidly. Witnessing a surge in similar treatment options that pose a challenge, to Vutrisirans market presence.

Supply Chain Landscape

Raw Material Procurement

BASF

DowDuPont

Chemical Synthesis

Merck KGaA

GlaxoSmithKline

Drug Formulation & Development
Alnylam Pharmaceuticals / Eli Lilly
End Use
Hospitals / Specialty Clinics / Retail Pharmacies
Raw Material Procurement

BASF

DowDuPont

Chemical Synthesis

Merck KGaA

GlaxoSmithKline

Drug Formulation & Development

Alnylam Pharmaceuticals

Eli Lilly

End Use

Hospitals

Specialty Clinics

Retail Pharmacies

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Drug Development
Pharmaceuticals
Alnylam Pharmaceuticals
Focuses on harnessing RNA interference to create a broad new class of drugs
Treatment of hATTR amyloidosis
Healthcare
Pfizer
Adopts a patient-centric approach to enhance treatment accessibility
Research in Molecular Biology
Biotechnology
Thermo Fisher Scientific
Employs cutting-edge technology for precise development and research

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Vutrisiran market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Vutrisiran in Hereditary Transthyretin-Mediated Amyloidosis (hATTR) and Polyneuropathy Management

Hereditary Transthyretin-Mediated Amyloidosis (hATTR)

As a ground-breaking therapeutic drug, Vutrisiran is primarily employed in managing Hereditary Transthyretin-Mediated Amyloidosis , a rare genetic condition that affects numerous organ systems. What sets this application apart is that Vutrisiran leverages RNA interference technology to strike at the root of hATTR, enabling, better control, progression slowdown, and symptom alleviation. Top market players in this field include leading pharmaceutical companies like Alnylam Pharmaceuticals, recognized for their innovation strengths and formidable market position.

Polyneuropathy Management

Vutrisiran is commonly used to help manage polyneuropathy by targeting the effects linked to the condition through reducing the productionof damaging transthyretin protein. This approach can slow down the advancementof polyneuropathy. Improve patients’ qualityof life. Those actively involved in this region include research organizations and pharmaceutical companies focused on treating diseases.

Vutrisiran vs. Substitutes:
Performance and Positioning Analysis

Vutrisiran distinguishes itself from its alternatives, offering a potentially higher efficacy profile, lower side effects, and a distinct delivery mechanism. This unique positioning places Vutrisiran poised for significant market growth

Vutrisiran
  • Patisiran /
  • Inotersen /
  • Revusiran
    Highly potent, proven to reduce key disease markers
    Potential side effects, not yet widely available
    Effective relief from symptoms, Affordable price points
    Delayed onset of action, Increased risk of side-effects

Vutrisiran vs. Substitutes:
Performance and Positioning Analysis

Vutrisiran

  • Highly potent, proven to reduce key disease markers
  • Potential side effects, not yet widely available

Patisiran / Inotersen / Revusiran

  • Effective relief from symptoms, Affordable price points
  • Delayed onset of action, Increased risk of side-effects

Vutrisiran distinguishes itself from its alternatives, offering a potentially higher efficacy profile, lower side effects, and a distinct delivery mechanism. This unique positioning places Vutrisiran poised for significant market growth

Loading...

Research Methodology

This market research methodology defines the Vutrisiran market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Vutrisiran across Clinicians, Patients, and Pharmaceuticals Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Alnylam Pharmaceuticals, Pfizer Inc., and Novartis AG by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Procurement, Chemical Synthesis, and Drug Formulation & Development. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Vutrisiran segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Procurement (BASF, DowDuPont), Chemical Synthesis (Merck KGaA, GlaxoSmithKline), and Drug Formulation & Development. Our parallel substitute analysis examines Patisiran, Inotersen, and Revusiran, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Alnylam Pharmaceuticals, Pfizer Inc., and Novartis AG, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Vutrisiran market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Vutrisiran Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 985 million
Revenue Forecast in 2034USD 4.47 billion
Growth RateCAGR of 18.3% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024832 million
Growth OpportunityUSD 3.6 billion
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024832 million USD
Market Size 20271.38 billion USD
Market Size 20291.93 billion USD
Market Size 20302.28 billion USD
Market Size 20344.47 billion USD
Market Size 20355.29 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredTherapeutic Application, Drug Mechanism, Distribution Channel, Producer Type, End User
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledAlnylam Pharmaceuticals, Pfizer Inc., Novartis AG, Sanofi, Amgen Inc., AstraZeneca, Abbott Laboratories, Eli Lilly and Company, Bristol-Myers Squibb, GlaxoSmithKline, Roche Holding AG and Johnson and Johnson
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Vutrisiran Market Size, Opportunities & Strategic Insights, by Therapeutic Application

4.1ATTR Amyloidosis
4.2Familial Amyloid Polyneuropathy
4.3Wild Type ATTR cardiomyopathy
4.4Others
Chapter 5

Vutrisiran Market Size, Opportunities & Strategic Insights, by Drug Mechanism

5.1siRNA therapy
5.2TTR gene silencing
5.3RNA interference-based therapy
Chapter 6

Vutrisiran Market Size, Opportunities & Strategic Insights, by Distribution Channel

6.1Hospital Pharmacies
6.2Retail Pharmacies
6.3Online Pharmacies
Chapter 7

Vutrisiran Market Size, Opportunities & Strategic Insights, by Producer Type

7.1Bio-Pharmaceutical Companies
7.2Clinical Research Organizations
7.3Medical Institutions
Chapter 8

Vutrisiran Market Size, Opportunities & Strategic Insights, by End User

8.1Clinicians
8.2Patients
8.3Pharmaceuticals
8.4Others
Chapter 9

Vutrisiran Market, by Region

9.1North America Vutrisiran Market Size, Opportunities, Key Trends & Strategic Insights
9.1.1U.S.
9.1.2Canada
9.2Europe Vutrisiran Market Size, Opportunities, Key Trends & Strategic Insights
9.2.1Germany
9.2.2France
9.2.3UK
9.2.4Italy
9.2.5The Netherlands
9.2.6Rest of EU
9.3Asia Pacific Vutrisiran Market Size, Opportunities, Key Trends & Strategic Insights
9.3.1China
9.3.2Japan
9.3.3South Korea
9.3.4India
9.3.5Australia
9.3.6Thailand
9.3.7Rest of APAC
9.4Middle East & Africa Vutrisiran Market Size, Opportunities, Key Trends & Strategic Insights
9.4.1Saudi Arabia
9.4.2United Arab Emirates
9.4.3South Africa
9.4.4Rest of MEA
9.5Latin America Vutrisiran Market Size, Opportunities, Key Trends & Strategic Insights
9.5.1Brazil
9.5.2Mexico
9.5.3Rest of LA
9.6CIS Vutrisiran Market Size, Opportunities, Key Trends & Strategic Insights
9.6.1Russia
9.6.2Rest of CIS
Chapter 10

Competitive Landscape

10.1Competitive Dashboard & Market Share Analysis
10.2Company Profiles (Overview, Financials, Developments, SWOT)
10.2.1Alnylam Pharmaceuticals
10.2.2Pfizer Inc.
10.2.3Novartis AG
10.2.4Sanofi
10.2.5Amgen Inc.
10.2.6AstraZeneca
10.2.7Abbott Laboratories
10.2.8Eli Lilly and Company
10.2.9Bristol-Myers Squibb
10.2.10GlaxoSmithKline
10.2.11Roche Holding AG
10.2.12Johnson and Johnson